# Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

> **NCT01491763** · PHASE4 · UNKNOWN · sponsor: **PETHEMA Foundation** · enrollment: 70 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia Ph Positive

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT01491763
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491763, "Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01491763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*